Last 12 months
Inside the activity.
0 purchase rows · 19 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 2 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 3 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 4 |
| Sep 2026 | 0 | 5 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 24, 2020 Filed Aug 25, 2020 20:55 UTC |
Hoge StephenPresident
|
SaleCommon Stock | 800 | $67.29 | $53,832.00 |
DisclosureSEC source: 0001127602-20-024227 · form4.xml · nonDerivative · entry 6 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,946,530 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on June 1, 2020. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $67.12 to $67.56. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 24, 2020 Filed Aug 25, 2020 20:55 UTC |
Hoge StephenPresident
|
SaleCommon Stock | 1,996 | $66.38 | $132,494.48 |
DisclosureSEC source: 0001127602-20-024227 · form4.xml · nonDerivative · entry 5 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,947,330 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on June 1, 2020. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $65.99 to $66.99. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 24, 2020 Filed Aug 25, 2020 20:55 UTC |
Hoge StephenPresident
|
SaleCommon Stock | 7,079 | $65.31 | $462,329.49 |
DisclosureSEC source: 0001127602-20-024227 · form4.xml · nonDerivative · entry 4 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,949,326 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on June 1, 2020. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.98 to $65.98. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 24, 2020 Filed Aug 25, 2020 20:55 UTC |
Hoge StephenPresident
|
SaleCommon Stock | 7,489 | $64.53 | $483,265.17 |
DisclosureSEC source: 0001127602-20-024227 · form4.xml · nonDerivative · entry 3 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,956,405 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on June 1, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.97 to $64.97. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 24, 2020 Filed Aug 25, 2020 20:55 UTC |
Hoge StephenPresident
|
SaleCommon Stock | 2,636 | $63.65 | $167,781.40 |
DisclosureSEC source: 0001127602-20-024227 · form4.xml · nonDerivative · entry 2 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,963,894 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on June 1, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.93 to $63.93. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 24, 2020 Filed Aug 25, 2020 20:55 UTC |
Hoge StephenPresident
|
Exercise / conversionCommon Stock | 10,000 | $0.99 | $9,900.00 |
DisclosureSEC source: 0001127602-20-024227 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,966,530 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on June 1, 2020. Read SEC document |
| August 24, 2020 Filed Aug 25, 2020 20:53 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $19.15 | $0.00 |
DisclosureSEC source: 0001127602-20-024222 · form4.xml · derivative · entry 11 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,790 Underlying: Common Stock · 10,000 shares Expires 2026-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F8 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| August 24, 2020 Filed Aug 25, 2020 20:53 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $12.21 | $0.00 |
DisclosureSEC source: 0001127602-20-024222 · form4.xml · derivative · entry 10 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,412 Underlying: Common Stock · 5,000 shares Expires 2027-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F7 · derivative.exercise_date: 25% of this option vested and became exercisable on February 22, 2018 with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| August 24, 2020 Filed Aug 25, 2020 20:53 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001127602-20-024222 · form4.xml · derivative · entry 9 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,195 Underlying: Common Stock · 10,000 shares Expires 2029-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| August 24, 2020 Filed Aug 25, 2020 20:53 UTC |
Zaks Tal ZviChief Medical Officer
|
SaleCommon Stock | 1,100 | $67.31 | $74,041.00 |
DisclosureSEC source: 0001127602-20-024222 · form4.xml · nonDerivative · entry 8 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $67.15 to $67.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 24, 2020 Filed Aug 25, 2020 20:53 UTC |
Zaks Tal ZviChief Medical Officer
|
SaleCommon Stock | 2,058 | $66.40 | $136,651.20 |
DisclosureSEC source: 0001127602-20-024222 · form4.xml · nonDerivative · entry 7 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,100 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $66.04 to $66.97. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 24, 2020 Filed Aug 25, 2020 20:53 UTC |
Zaks Tal ZviChief Medical Officer
|
SaleCommon Stock | 8,690 | $65.35 | $567,891.50 |
DisclosureSEC source: 0001127602-20-024222 · form4.xml · nonDerivative · entry 6 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,158 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $65.02 to $66.02. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 24, 2020 Filed Aug 25, 2020 20:53 UTC |
Zaks Tal ZviChief Medical Officer
|
SaleCommon Stock | 9,849 | $64.56 | $635,851.44 |
DisclosureSEC source: 0001127602-20-024222 · form4.xml · nonDerivative · entry 5 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,848 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.01 to $65.01. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 24, 2020 Filed Aug 25, 2020 20:53 UTC |
Zaks Tal ZviChief Medical Officer
|
SaleCommon Stock | 3,303 | $63.65 | $210,235.95 |
DisclosureSEC source: 0001127602-20-024222 · form4.xml · nonDerivative · entry 4 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,697 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.98 to $63.98. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 24, 2020 Filed Aug 25, 2020 20:53 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionCommon Stock | 10,000 | $19.15 | $191,500.00 |
DisclosureSEC source: 0001127602-20-024222 · form4.xml · nonDerivative · entry 3 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| August 24, 2020 Filed Aug 25, 2020 20:53 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionCommon Stock | 5,000 | $12.21 | $61,050.00 |
DisclosureSEC source: 0001127602-20-024222 · form4.xml · nonDerivative · entry 2 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| August 24, 2020 Filed Aug 25, 2020 20:53 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionCommon Stock | 10,000 | $20.93 | $209,300.00 |
DisclosureSEC source: 0001127602-20-024222 · form4.xml · nonDerivative · entry 1 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| August 21, 2020 Filed Aug 25, 2020 20:50 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 802 | $67.83 | $54,399.66 |
DisclosureSEC source: 0001127602-20-024216 · form4.xml · nonDerivative · entry 3 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 441,856 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $67.73 to $67.99. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| August 21, 2020 Filed Aug 25, 2020 20:50 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 4,275 | $67.17 | $287,151.75 |
DisclosureSEC source: 0001127602-20-024216 · form4.xml · nonDerivative · entry 2 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 442,658 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $66.71 to $67.70. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| August 21, 2020 Filed Aug 25, 2020 20:50 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 5,969 | $66.19 | $395,088.11 |
DisclosureSEC source: 0001127602-20-024216 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 446,933 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $65.67 to $66.67. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| August 20, 2020 Filed Aug 21, 2020 20:21 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 10,000 | $67.80 | $678,000.00 |
DisclosureSEC source: 0001127602-20-024037 · form4.xml · nonDerivative · entry 4 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,794,880 F6 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 18, 2018, as amended on May 21, 2020. F7 · ownership.nature: These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| August 20, 2020 Filed Aug 21, 2020 20:21 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 8,824 | $67.80 | $598,267.20 |
DisclosureSEC source: 0001127602-20-024037 · form4.xml · nonDerivative · entry 3 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 9,135,960 F4 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 18, 2018, as amended on September 16, 2019. F5 · ownership.nature: These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 20:21 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
GiftCommon Stock | 1,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-024037 · form4.xml · nonDerivative · entry 2 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,703,868 F2 · kind: The reported disposition was effected pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2020. F3 · price: The reported disposition represents a bona fide charitable gift made by the reporting person. Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 20:21 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 9,000 | $66.74 | $600,660.00 |
DisclosureSEC source: 0001127602-20-024037 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,704,868 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as amended on May 21, 2020. Read SEC document |
| August 17, 2020 Filed Aug 18, 2020 20:24 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $19.15 | $0.00 |
DisclosureSEC source: 0001127602-20-023815 · form4.xml · derivative · entry 5 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,790 Underlying: Common Stock · 10,000 shares Expires 2026-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F2 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| August 17, 2020 Filed Aug 18, 2020 20:24 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0001127602-20-023815 · form4.xml · derivative · entry 4 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,195 Underlying: Common Stock · 10,000 shares Expires 2029-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| August 17, 2020 Filed Aug 18, 2020 20:24 UTC |
Zaks Tal ZviChief Medical Officer
|
SaleCommon Stock | 20,000 | $69.06 | $1,381,200.00 |
DisclosureSEC source: 0001127602-20-023815 · form4.xml · nonDerivative · entry 3 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| August 17, 2020 Filed Aug 18, 2020 20:24 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionCommon Stock | 10,000 | $19.15 | $191,500.00 |
DisclosureSEC source: 0001127602-20-023815 · form4.xml · nonDerivative · entry 2 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| August 17, 2020 Filed Aug 18, 2020 20:24 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionCommon Stock | 10,000 | $20.93 | $209,300.00 |
DisclosureSEC source: 0001127602-20-023815 · form4.xml · nonDerivative · entry 1 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| August 17, 2020 Filed Aug 20, 2020 00:20 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
OtherCommon Stock | 50,010 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-023936 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,713,868 F1 · kind: Represents the receipt of shares by the reporting person pursuant to pro rata distributions-in-kind, without consideration, of shares of the company's common stock effected on August 17, 2020 by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") to the partners of Flagship Fund IV and by its general partner, Flagship Ventures Fund IV General Partner, LLC. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| August 17, 2020 Filed Aug 20, 2020 00:15 UTC |
Flagship Ventures Fund IV General Partner LLCDirector · 10% owner
Flagship Ventures Fund IV, L.P.10% owner
Flagship Ventures Fund IV-Rx, L.P.10% owner
Afeyan NoubarDirector · 10% owner
|
OtherCommon Stock | 2,053,049 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-022975 · doc4.xml · nonDerivative · entry 3 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · Director · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · kind: On August 17, 2020, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner, LLC ("Flagship Fund IV GP"), pro rata and without consideration, 7,550,810 shares and 1,449,190 shares, respectively, of the Issuer's common stock. Flagship Fund IV GP, in turn, distributed to its members, pro rata and without consideration, the 1,763,172 shares and 289,877 shares it received from Flagship Fund IV and Flagship Fund IV-Rx, respectively. Noubar B. Afeyan, Ph.D., sole manager of Flagship Fund IV GP, received 711,876 shares through Flagship Fund IV GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F1 · price: On August 17, 2020, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner, LLC ("Flagship Fund IV GP"), pro rata and without consideration, 7,550,810 shares and 1,449,190 shares, respectively, of the Issuer's common stock. Flagship Fund IV GP, in turn, distributed to its members, pro rata and without consideration, the 1,763,172 shares and 289,877 shares it received from Flagship Fund IV and Flagship Fund IV-Rx, respectively. Noubar B. Afeyan, Ph.D., sole manager of Flagship Fund IV GP, received 711,876 shares through Flagship Fund IV GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F4 · ownership.nature: Shares held by Flagship Fund IV GP. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV GP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| August 17, 2020 Filed Aug 20, 2020 00:15 UTC |
Flagship Ventures Fund IV General Partner LLCDirector · 10% owner
Flagship Ventures Fund IV, L.P.10% owner
Flagship Ventures Fund IV-Rx, L.P.10% owner
Afeyan NoubarDirector · 10% owner
|
OtherCommon Stock | 1,449,190 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-022975 · doc4.xml · nonDerivative · entry 2 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · Director · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,971,576 F1 · kind: On August 17, 2020, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner, LLC ("Flagship Fund IV GP"), pro rata and without consideration, 7,550,810 shares and 1,449,190 shares, respectively, of the Issuer's common stock. Flagship Fund IV GP, in turn, distributed to its members, pro rata and without consideration, the 1,763,172 shares and 289,877 shares it received from Flagship Fund IV and Flagship Fund IV-Rx, respectively. Noubar B. Afeyan, Ph.D., sole manager of Flagship Fund IV GP, received 711,876 shares through Flagship Fund IV GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F1 · price: On August 17, 2020, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner, LLC ("Flagship Fund IV GP"), pro rata and without consideration, 7,550,810 shares and 1,449,190 shares, respectively, of the Issuer's common stock. Flagship Fund IV GP, in turn, distributed to its members, pro rata and without consideration, the 1,763,172 shares and 289,877 shares it received from Flagship Fund IV and Flagship Fund IV-Rx, respectively. Noubar B. Afeyan, Ph.D., sole manager of Flagship Fund IV GP, received 711,876 shares through Flagship Fund IV GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F3 · ownership.nature: Shares held by Flagship Fund IV-Rx. Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| August 17, 2020 Filed Aug 20, 2020 00:15 UTC |
Flagship Ventures Fund IV General Partner LLCDirector · 10% owner
Flagship Ventures Fund IV, L.P.10% owner
Flagship Ventures Fund IV-Rx, L.P.10% owner
Afeyan NoubarDirector · 10% owner
|
OtherCommon Stock | 7,550,810 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-022975 · doc4.xml · nonDerivative · entry 1 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · Director · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Flagship Ventures Fund IV-Rx, L.P. · CIK 0001590973 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 14,435,589 F1 · kind: On August 17, 2020, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner, LLC ("Flagship Fund IV GP"), pro rata and without consideration, 7,550,810 shares and 1,449,190 shares, respectively, of the Issuer's common stock. Flagship Fund IV GP, in turn, distributed to its members, pro rata and without consideration, the 1,763,172 shares and 289,877 shares it received from Flagship Fund IV and Flagship Fund IV-Rx, respectively. Noubar B. Afeyan, Ph.D., sole manager of Flagship Fund IV GP, received 711,876 shares through Flagship Fund IV GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F1 · price: On August 17, 2020, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") distributed to its limited partners and sole general partner, Flagship Ventures Fund IV General Partner, LLC ("Flagship Fund IV GP"), pro rata and without consideration, 7,550,810 shares and 1,449,190 shares, respectively, of the Issuer's common stock. Flagship Fund IV GP, in turn, distributed to its members, pro rata and without consideration, the 1,763,172 shares and 289,877 shares it received from Flagship Fund IV and Flagship Fund IV-Rx, respectively. Noubar B. Afeyan, Ph.D., sole manager of Flagship Fund IV GP, received 711,876 shares through Flagship Fund IV GP's distribution. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended. F2 · ownership.nature: Shares held by Flagship Fund IV. Flagship Fund IV GP is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| August 14, 2020 Filed Aug 18, 2020 20:10 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 400 | $70.03 | $28,012.00 |
DisclosureSEC source: 0001127602-20-023793 · form4.xml · nonDerivative · entry 3 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 452,902 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $69.96 to $70.11. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| August 14, 2020 Filed Aug 18, 2020 20:10 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 5,047 | $69.47 | $350,615.09 |
DisclosureSEC source: 0001127602-20-023793 · form4.xml · nonDerivative · entry 2 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 453,302 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $68.95 to $69.95. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| August 14, 2020 Filed Aug 18, 2020 20:10 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 5,599 | $68.47 | $383,363.53 |
DisclosureSEC source: 0001127602-20-023793 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 458,349 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $67.93 to $68.89. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| August 13, 2020 Filed Aug 14, 2020 20:40 UTC |
Hoge StephenPresident
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001127602-20-023610 · form4.xml · derivative · entry 12 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 847,431 Underlying: Common Stock · 10,000 shares Expires 2023-08-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on June 1, 2020. F9 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| August 13, 2020 Filed Aug 14, 2020 20:40 UTC |
Hoge StephenPresident
|
SaleCommon Stock | 700 | $68.49 | $47,943.00 |
DisclosureSEC source: 0001127602-20-023610 · form4.xml · nonDerivative · entry 10 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,956,530 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on June 1, 2020. F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $68.33 to $68.81. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 13, 2020 Filed Aug 14, 2020 20:40 UTC |
Hoge StephenPresident
|
SaleCommon Stock | 4,300 | $67.80 | $291,540.00 |
DisclosureSEC source: 0001127602-20-023610 · form4.xml · nonDerivative · entry 9 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,957,230 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on June 1, 2020. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $67.29 to $68.28. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 13, 2020 Filed Aug 14, 2020 20:40 UTC |
Hoge StephenPresident
|
SaleCommon Stock | 10,000 | $69.05 | $690,500.00 |
DisclosureSEC source: 0001127602-20-023610 · form4.xml · nonDerivative · entry 8 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,961,530 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on June 1, 2020. Read SEC document |
| August 13, 2020 Filed Aug 14, 2020 20:40 UTC |
Hoge StephenPresident
|
Exercise / conversionCommon Stock | 10,000 | $0.99 | $9,900.00 |
DisclosureSEC source: 0001127602-20-023610 · form4.xml · nonDerivative · entry 7 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,971,530 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on June 1, 2020. Read SEC document |
| August 13, 2020 Filed Aug 14, 2020 20:48 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 10,000 | $69.05 | $690,500.00 |
DisclosureSEC source: 0001127602-20-023615 · form4.xml · nonDerivative · entry 3 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,804,880 F4 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 18, 2018, as amended on September 16, 2019. F5 · ownership.nature: These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| August 13, 2020 Filed Aug 14, 2020 20:47 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 10,000 | $69.05 | $690,500.00 |
DisclosureSEC source: 0001127602-20-023614 · form4.xml · nonDerivative · entry 3 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,804,880 F4 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 18, 2018, as amended on September 16, 2019. F5 · ownership.nature: These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 20:40 UTC |
Hoge StephenPresident
|
SaleCommon Stock | 100 | $74.06 | $7,406.00 |
DisclosureSEC source: 0001127602-20-023610 · form4.xml · nonDerivative · entry 6 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,961,530 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on June 1, 2020. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 20:40 UTC |
Hoge StephenPresident
|
SaleCommon Stock | 200 | $73.18 | $14,636.00 |
DisclosureSEC source: 0001127602-20-023610 · form4.xml · nonDerivative · entry 5 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,961,630 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on June 1, 2020. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $72.90 to $73.45. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 20:40 UTC |
Hoge StephenPresident
|
SaleCommon Stock | 230 | $72.01 | $16,562.30 |
DisclosureSEC source: 0001127602-20-023610 · form4.xml · nonDerivative · entry 4 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,961,830 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on June 1, 2020. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.64 to $72.33. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 20:40 UTC |
Hoge StephenPresident
|
SaleCommon Stock | 400 | $70.77 | $28,308.00 |
DisclosureSEC source: 0001127602-20-023610 · form4.xml · nonDerivative · entry 3 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,962,060 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on June 1, 2020. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.57 to $71.03. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 20:40 UTC |
Hoge StephenPresident
|
SaleCommon Stock | 3,138 | $69.92 | $219,408.96 |
DisclosureSEC source: 0001127602-20-023610 · form4.xml · nonDerivative · entry 2 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,962,460 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on June 1, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $69.56 to $70.46. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 20:40 UTC |
Hoge StephenPresident
|
SaleCommon Stock | 932 | $69.05 | $64,354.60 |
DisclosureSEC source: 0001127602-20-023610 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,965,598 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on June 1, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $68.55 to $69.48. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| August 12, 2020 Filed Aug 14, 2020 20:48 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
GiftCommon Stock | 1,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-023615 · form4.xml · nonDerivative · entry 2 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,663,858 F2 · kind: The reported disposition was effected pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2020. F3 · price: The reported disposition represents a bona fide charitable gift made by the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.